Trials / Completed
CompletedNCT05936567
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | oral; tablet |
| DRUG | Placebo | oral; tablet |
Timeline
- Start date
- 2023-07-31
- Primary completion
- 2025-02-28
- Completion
- 2025-10-09
- First posted
- 2023-07-07
- Last updated
- 2026-03-12
- Results posted
- 2026-03-12
Locations
42 sites across 3 countries: United States, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05936567. Inclusion in this directory is not an endorsement.